J. Hoffman

发表

Abstract 4515: A phase 1 randomized, open-label, fixed-sequence, 2-period study of the effect of multiple doses of rifampin on palbociclib (PD-0332991) pharmacokinetics in healthy volunteers

M. O’Gorman, J. Hoffman, A. Płotka, 2015 .

Physiologically Based Pharmacokinetic Modeling of Palbociclib

J. Hoffman, C. Loi, Diane D. Wang, 2017, Journal of clinical pharmacology.

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

H. Iwata, Y. Im, Kenichi Inoue, 2017, Journal of global oncology.

Fixed Dosing versus Body‐Size‐Based Dosing for Therapeutic Biologics—A Clinical Pharmacology Strategy

J. Hoffman, Diane D. Wang, K. Parivar, 2015 .

Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation.

I. Jang, J. Hoffman, Joseph D Ma, 2012, International journal of clinical pharmacology and therapeutics.

Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer

H. Rugo, K. Wilner, R. Finn, 2018, Anti-cancer drugs.

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors

J. Chakrabarti, Z. Wainberg, J. Hoffman, 2019, Anti-cancer drugs.

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors

J. Chakrabarti, S. Piha-Paul, Haihong Shi, 2021, Clinical Pharmacokinetics.

76PA PHASE 1 OPEN-LABEL FIXED-SEQUENCE TWO-PERIOD CROSSOVER STUDY OF THE EFFECT OF MULTIPLE DOSES OF TAMOXIFEN ON PALBOCICLIB (PD-0332991) PHARMACOKINETICS IN HEALTHY MALE VOLUNTEERS

L. Kirkovsky, M. O’Gorman, J. Hoffman, 2014 .

Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.

M. Dowsett, S. Loi, H. Iwata, 2017, The oncologist.

Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.

B. Melichar, Xin Huang, C. Yen, 2021, Oral oncology.

Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function

Haihong Shi, M. O’Gorman, J. Hoffman, 2020, Cancer Chemotherapy and Pharmacology.

Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS).

B. Melichar, K. Kern, J. Martini, 2019, Journal of Clinical Oncology.